Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
HPV
PD-L1
cervical cancer
neuroendocrine carcinomas
next-generation sequencing
targeted therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Mar 2021
10 Mar 2021
Historique:
received:
28
01
2021
revised:
06
03
2021
accepted:
08
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Neuroendocrine carcinoma of the cervix (NECC) is a rare and highly aggressive tumor with no efficient treatment. We examined genetic features of NECC and identified potential therapeutic targets. A total of 272 patients with cervical cancer (25 NECC, 180 squamous cell carcinoma, 53 adenocarcinoma, and 14 adenosquamous carcinoma) were enrolled. Somatic hotspot mutations in 50 cancer-related genes were detected using the Ion AmpliSeq Cancer Hotspot Panel v2. Human papillomavirus (HPV)-positivity was examined by polymerase chain reaction (PCR)-based testing and in situ hybridization assays. Programmed cell death-ligand 1 (PD-L1) expression was examined using immunohistochemistry. Somatic mutation data for 320 cases of cervical cancer from the Project GENIE database were also analyzed. NECC showed similar (
Identifiants
pubmed: 33802174
pii: cancers13061215
doi: 10.3390/cancers13061215
pmc: PMC8001835
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Sci Transl Med. 2018 Jan 17;10(424):
pubmed: 29343622
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Gynecol Oncol. 2018 Feb;148(2):422-429
pubmed: 29248196
Cell. 2012 Feb 3;148(3):409-20
pubmed: 22304912
Cancer Discov. 2018 Jul;8(7):836-849
pubmed: 29657135
Mol Cancer. 2011 Jun 10;10:71
pubmed: 21663621
Mod Pathol. 2021 Mar;34(3):532-541
pubmed: 33239737
Am J Surg Pathol. 2018 Jun;42(6):750-760
pubmed: 29505425
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Sci Rep. 2017 Oct 20;7(1):13682
pubmed: 29057919
Nat Rev Cancer. 2013 Nov;13(11):788-99
pubmed: 24132110
Minerva Endocrinol. 2019 Dec;44(4):378-386
pubmed: 30991795
JCO Precis Oncol. 2020 Sep 3;4:
pubmed: 33015532
Int J Gynecol Cancer. 2019 Jul;29(6):986-995
pubmed: 31263021
Cancers (Basel). 2019 Dec 30;12(1):
pubmed: 31905960
BMC Cancer. 2018 May 4;18(1):530
pubmed: 29728073
Am J Surg Pathol. 2011 Nov;35(11):1679-84
pubmed: 21997688
Oncotarget. 2017 Jul 11;8(28):45323-45334
pubmed: 28484083
Histopathology. 2007 Sep;51(3):305-12
pubmed: 17727473
J Clin Invest. 2018 Feb 1;128(2):805-815
pubmed: 29337305
Gynecol Oncol Rep. 2014 Oct 25;10:28-9
pubmed: 26075998
JAMA Oncol. 2016 Jun 1;2(6):823-6
pubmed: 27010835
Papillomavirus Res. 2018 Jun;5:134-142
pubmed: 29555602
Clin Cancer Res. 2018 Mar 15;24(6):1287-1295
pubmed: 29298798
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Cancer Discov. 2019 Feb;9(2):248-263
pubmed: 30373917
Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6280-6287
pubmed: 30338793
J Clin Oncol. 2007 Aug 20;25(24):3628-34
pubmed: 17704412
Dev Biol. 2011 Jun 1;354(1):87-101
pubmed: 21458439
Gynecol Oncol. 2016 Jun;141(3):588-591
pubmed: 27079212
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Cancer. 2018 Feb 15;124(4):807-815
pubmed: 29211313
Mod Pathol. 1991 Sep;4(5):586-93
pubmed: 1722042
J Obstet Gynaecol Res. 2019 Feb;45(2):289-298
pubmed: 30426591
Gynecol Oncol. 2020 Jan;156(1):203-210
pubmed: 31757465
Am J Surg Pathol. 1991 Jan;15(1):28-32
pubmed: 1845923
Cancer Discov. 2019 Feb;9(2):230-247
pubmed: 30373918
Gynecol Oncol. 2018 Jan;148(1):139-146
pubmed: 29113721
Arch Pathol Lab Med. 2019 Mar;143(3):330-337
pubmed: 30028179
Gynecol Oncol Res Pract. 2017 Feb 2;4:3
pubmed: 28174665
Papillomavirus Res. 2018 Dec;6:41-45
pubmed: 30347290
PLoS One. 2020 Jun 16;15(6):e0234505
pubmed: 32544169